相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels
Alessandro Ciresi et al.
CLINICAL ENDOCRINOLOGY (2013)
Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register
Christof Schoefl et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)
Gemma Sesmilo et al.
PITUITARY (2013)
Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
C. E. Higham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Hypothesis: Extra-hepatic acromegaly: a new paradigm?
Sebastian J. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study
M. Marazuela et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Lipodystrophy during pegvisomant therapy: a case report and review of the literature
D. Buyuktas et al.
CLINICS (2010)
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Ignacio Bernabeu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Subcutaneous lipoatrophy induced by long-term pegvisomant administration
Cannavo Salvatore et al.
CLINICAL ENDOCRINOLOGY (2009)
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy
Monica Marazuela et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Pegvisomant increases intra-abdominal fat in patients with acromegaly:: a pilot study
U. Ploeckinger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Lipodystrophy in patients with acromegaly receiving pegvisomant
Vivien S. Bonert et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Pegvisomant-induced lipohypertrophy:: Report of a case with histopathology
Monica Marazuela et al.
ANNALS OF INTERNAL MEDICINE (2007)
AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects
Marie Bex et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant
Craig Parkinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant
Pietro Maffei et al.
ANNALS OF INTERNAL MEDICINE (2006)
Predictors and rates of treatment-resistant tumor growth in acromegaly
GM Besser et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly
A Atmaca et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2005)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
